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Purpose: Myotonic dystrophy, also known as dystrophia myotonica (DM), is an autosomal dominant 
disorder with 2 genetically distinct forms. DM type 1 (DM1) is the more common form and is caused by 
abnormal expansion of cytosine/thymine/guanine (CTG) repeats in the DM protein kinase (DMPK ) gene. 
Our study aimed to determine whether the age of onset is correlated with CTG repeat length in a population 
of pediatric patients with DM1.
Methods: We retrospectively identified 30 pediatric patients with DM1 that underwent DMPK testing, of 
which the clinical data of 17 was sufficient. The cohort was divided into 2 subgroups based on the clinical 
phenotype (congenital-onset vs. late-onset) and number of CTG repeats (<1,000 vs. ≥1,000).
Results: We found no significant difference between the age of onset and CTG repeat length in our 
pediatric patient population. Based on clinical subgrouping, we found that the congenital-onset subgroup 
was statistically different with respect to several variables, including prematurity, rate of admission 
to neonatal intensive care unit, need for respiratory support at birth, hypotonia, dysphagia, ventilator 
dependence, and functional status on last visit, compared to the late-onset subgroup. Based on genetic 
subgrouping, we found a single variable (poor feeding in neonate) that was significantly different in the 
large CTG subgroup than that in the small CTG subgroup.
Conclusion: Clinical variables exhibiting statistically significant differences between the subgroups 
should be focused on prognosis and designing tailored management approaches for the patients; our 
findings will contribute to achieve this important goal for treating patients with DM1.
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Introduction 
Myotonic dystrophy (also known as dystrophia myotonica; DM) is an autosomal dominant 
disorder characterized by muscular dystrophy, myotonia, cataract, hypogonadism, and cardiac 
conduction disorders. It is classified into 2 types, DM type 1 (DM1) and DM type 2 (DM2), 
based on the causative genetic mutation1); DM1 is more severe and common with an estimated 
prevalence of 1 in 8,000.2,3) 
Although diagnosis can be made on the basis of several symptoms, it is often difficult to 
confirm the diagnosis, solely based on clinical symptoms, in mild cases.4) For such instances, 
direct analysis of the cytosine/thymine/guanine (CTG) trinucleotide repeat in the 3' untranslat­
ed region of myotonic dystrophy protein kinase (DMPK) gene on chromosome 19 by Southern 
blotting enables a reliable diagnosis,5) since DM1 is known to result from an abnormal number 
of CTG repeats.2,6)
Severity of DM1 varies with the number of CTG repeats.6,7) While mildly affected patients 
have 50–150 repeats, patients with classic DM1 have 100–1,000 repeats, and those with the 
congenital form of the disease have >2,000 repeats.2,8,9) However, due to insufficient number of 
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CTG” subgroup included individuals with >1,000 CTG repeats while 
the “small CTG” subgroup consisted of individuals with <1,000 CTG 
repeats. Currently, the most widely known classification of disease 
severity based on CTG repeats is as follows: normal individuals (5– 
37 repeats), mildly affected patients (50–150 repeats), patients with 
classic DM1 (100–1,000 repeats), and patients with congenital DM1 
(>2,000 repeats). As stated earlier, there is no established cutoff 
val ue or classification standard for the distribution of the patients 
according to CTG repeat length, especially over 1,000–2,000 repeats. 
Since 23% of patients had congenital DM1, possessing 1,000–2,000 
repeats of the CTG trinucleotide, in our patient group, we set >1,000 
repeats as the threshold for classification of congenital DM1 in our 
cohort.
3. Statistics
All analyses were conducted using IBM SPSS Statistics ver. 20.0 
(IBM Co., Armonk, NY, USA). We used Fisher exact test to calculate 
P values between each set of subgroups. Spearman rank correlation 
was used to identify whether there was a relationship between 
length of the CTG repeat region and age of onset, whereas the Mann­
Whitney U test was used to compare time periods between birth, 
symptom onset, and diagnosis. A P value of <0.05 was considered 
statistically significant.
patients, investigation of various hypotheses regarding diagnostic 
tools and treatment of DM1 has been limited. In fact, there is 
currently no established cutoff value or classification standard 
for the distribution of patients, genetically diagnosed with DM1, 
according to CTG repeat length.
Thus, our aim was to determine whether a correlation between 
severity of clinical phenotype and length of the CTG repeat region 




We identified 30 patients with DM1, who were followed up in 2 
centers of our hospital (Gangnam Severance Hospital and Severance 
Children’s Hospital), through a retrospective study (Fig. 1). All 
participants were diagnosed with DM1 by genetic testing of DMPK 
from November 2005 to June 2017. Thirteen patients were excluded 
from the study due to poor clinical data. Our final cohort of 17 pati­
ents with DM1 had sufficient clinical data, including clinical symp­
toms, age of onset, previous history, length of CTG repeat, labo ratory 
and radiological findings, and follow­up data. Institutional Review 
Board, Gangnam Severance Hospital, Yonsei University College of 
Medicine (approval number: 3­2017­0263) and written informed 
consent was obtained from the parents or legal guardians of all 
patients.
2. Subgroup analysis
We derived 2 different sets of subgroups for intergroup compari­
son based on 2 criteria, clinical and genetic. In clinical subgrouping, 
patients were classified based on the onset time of symptoms; the 
ones whose symptoms appeared within one month formed the con ­
genital­onset subgroup while the others with later onset of symp­
toms formed the late­onset subgroup. In genetic subgrouping, pati­
ents were classified based on the number of CTG repeats. The “Large 
Patients with myotonic dystrophy 1 (n=30) 
Mutation of DMPK gene (Reported in Nov. 2005–Junbe. 2017) 
Patients with sufficient clinical data (n=17) 
Including size of repeated CTG, clinical symptoms, age of onset, hisotry, 
laboratory/radiologic finding, and follow-up data 
Lack of clinical data (n=13) 
Genotype-phenotype correlation 
Clinical subgrouping 
Congenital-onset (n=10) vs. late-onset (n=7) 
Genetic subgrouping 
Larger CTG (n=9) vs. smaller CTG (n=8) 
Fig. 1. Subgroup analysis of patients with myotonic dystrophy. CTG, 
cytosine/thymine/guanine.




  Male 12 (70.6)
  Female 5 (29.4)
Time period between birth, symptom onset, and genetic diagnosis (yr)
  From birth to symptom onset 4.1±5.8
  From symptom onset to diagnosis 1.6±2.7
  From birth to diagnosis 5.7±7.3
Age of onset
  Neonate (<1 mo) 10 (58.8)
  Infant and older (≥1 mo) 7 (41.2)
     <5 yr 1/7 (14.3)
     5–10 yr 3/7 (42.9)
     10–15 yr 3/7 (42.9)
CTG repeat length 
  100–500 5 (29.4)
  500–1,000 3 (17.6)
  1,000–2,000 4 (23.5)
  ≥2,000 5 (29.4)
Values are presented as number (%) or mean±standard deviation.
CTG, cytosine/thymine/guanine.
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Results
1. Demographics
Our cohort consisted of 12 male (70.6%) and 5 female patients 
(29.4%) (Table 1). The time period from diagnosis to onset of 
symptoms was 1.6±2.7 years, and that from birth to onset was 4.1± 
5.8 years. Ten patients were found to have congenital­onset DM1 
whose symp toms manifested within 1 month from birth, 7 were 
found to be late­onset patients whose symptoms manifested after 1 
month from birth. We observed a varied distribution in the number 
of patients classified according to CTG trinucleotide repeat length, 
but there was no correlation between age of onset and length of 
CTG repeat in our pediatric patient population. However, there was 
a nonsignificant ten dency towards an inverse relationship on scatter 
plot (Correlation coeffi cient=­0.194, P=0.384).
2. Clinical subgrouping
1) General characteristics and clinical manifestations
As shown in Table 2, among our clinically derived subgroups, the 
sex ratio was 6 male (60.0%) to 4 female patients (40.0%) in the con­
genital­onset subgroup and 6 male (85.7%) to 1 female patient (14.3 
%) in the late­onset subgroup. This difference in sex distribution was, 
however, not statistically significant. The first symptom to manifest 
Table 2. General characteristics and clinical manifestations of patients 





  Male 6 (60.0) 6 (85.7) 0.278
  Female 4 (40.0) 1 (14.3) 0.278
First symptom
  Hypotonia 10 (100) 0 (0) <0.001
  Myotonia 0 (0) 2 (28.6) 0.154
  Weakness 0 (0) 1 (14.3) 0.412
  Delayed development 0 (0) 2 (28.6) 0.154
  Gait disturbance 0 (0) 1 (14.3) 0.412
  Chest discomfort 0 (0) 1 (14.3) 0.412
Birth history
  Prenatal
    Decreased fetal movements 2/9 (22.2) 0/3 (0) 0.545
    Polyhydramnios 2/9 (22.2) 0/3 (0) 0.545
  At birth
    Prematurity
       Preterm 6 (60.0) 0/7 (0) 0.035
       Term 4 (40.0) 7/7 (100) 0.035
    IUP
       Less than 34 wk (<34 wk) 2 (20.0) 0 (0) 0.331
       Between 34 wk and 37 wk 5 (50.0) 0 (0) 0.044
       More than 37 wk (≥37 wk) 3 (30.0) 7 (100) 0.010
    Birth weight
      ELBW (<1,000 g) 0 (0) 0/5 (0) -
      VLBW (<1,500 g) 0 (0) 0/5 (0) -
      LBW (<2,500 g) 5 (50.0) 0/5 (0) 0.084
      Normal (≥2,500 g) 5 (50.0) 5/5 (100) 0.084
   IUGR 2 (20.0) 0/5 (0) 0.429
   Perinatal asphyxia 7 (70.0) 0/3 (0) 0.070
   NICU admission 10 (100) 0/3 (0) 0.003
   Need for respiratory support 9 (90.0) 0/3 (0) 0.014
Table 2. General characteristics and clinical manifestations of patients 






  History of muscular disease 6 (60.0) 4 (57.1) 0.646
Time period between birth, symptom 
onset, and genetic diagnosis (yr)
  From birth to symptom onset 0.1 (0.1–0.1) 9.9 (1.2–14.9) <0.001
  From symptom onset to diagnosis 0.1 (0.1–1.7)  2.0 (0.1–10.5) 0.007
  From birth to diagnosis 0.1 (0.1–1.7) 15.0 (4.5–20.4) <0.001
Systemic involvements
  Head and neck
     Cataract 0/10 (0) 1/7 (14.3) 0.412
  Cardiac
     Arrhythmia 0/10 (0) 1/7 (14.3) 0.412
  Gastrointestinal
     Poor feeding in neonate 8/10 (80.0) 2/7 (28.6) 0.052
     Dysphagia 8/10 (80.0) 1/7 (14.3) 0.015
     Intestinal pseudo-obstruction 0/10 (0) 0/7 (0) -
     Cholelithiasis 0/10 (0) 0/7 (0) -
  Respiratory
     Congenital respiratory distress 6 (60.0) 0 (0) 0.035
  Muscular
     Hypotonia in neonate 10 (100) 1 (14.3) <0.001
     Myotonia 4/4 (100) 5/5 (100) -
     Weakness 6/6 (100) 5/6 (83.3) 0.500
     Myotonic discharges on EMG 1/1 (100) 2/5 (40.0) 0.500
  Neurologic
     Delayed development or MR 5/6 (83.3) 5/7 (71.4) 0.563
CTG repeat length (n)
  100–500 3 (30.0) 2 (28.6) 0.686
  500–1,000 1 (10.0) 2 (28.6) 0.360
  1,000–2,000 4 (40.0) 0 (0) 0.088
  ≥2,000 2 (20.0) 3 (42.9) 0.314
Values are presented as number (%) or median (range).
IUP, intrauterine pregnancy; ELBW, extremely low birth weight; VLBW, very low 
birth weight; LBW, low birth weight; IUGR, intrauterine growth restriction; NICU, 
neonatal intensive care unit; EMG, electromyogram; MR, mental retardation; 
CTG, cytosine/thymine/guanine.
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in cases with DM1, though variable, included hypotonia, myotonia, 
weakness, delayed development, gait disturbance, and chest dis­
com fort. We found a significant difference in the occurrence of hy­
poto nia between patients from our clinical subgroups; hypotonia 
occurred in all patients from the congenital­onset subgroup while it 
was not at all reported in the late­onset subgroup. Furthermore, we 
found that birth and family history, including prematurity, neonatal 
intensive care unit (NICU) admission rate, and need for respiratory 
support, was significantly dominant in the congenital­onset sub­
group compared to those in the late­onset subgroup. Prematurity 
occurred in 60.0% of patients from the congenital­onset subgroup 
while it occurred in none in the late­onset subgroup (P=0.035); the 
proportion of NICU admission and need for respiratory support 
(100% and 90.0%, respectively) in the congenital­onset subgroup 
was high compared to none in the late­onset subgroup (P=0.003 and 
P=0.014, respectively). On the other hand, prenatal history, such as 
decreased fetal movements and polyhydramnios, had no statistically 
significant difference between the subgroups. We also found that the 
involved systems were variable and 4 clinical symptoms, specifically 
poor feeding in neonate, dysphagia, congenital respiratory distress, 
and hypotonia in neonate, were statisti cally more frequent in the 
congenital­onset subgroup, with frequencies of 80.0%, 80.0%, 
60.0%, and 100%, respectively. Furthermore, CTG repeat distribution 
in congenital­ and late­onset subgroups was not significantly 
different for patients with >2,000 CTG repeats (20.0% vs. 42.9%, 
respectively), 1,000–2,000 CTG repeats (40.0% vs. 0%, respectively), 
500–1,000 CTG repeats (10.0% vs. 28.6%, respectively), and 100–500 
CTG repeats (30.0% vs. 28.6%, respectively).
2) Diagnostic evaluation and functional status in the last visit
Although 31.3% of all patients showed increased creatinine 
kinase (CK), there was no significant difference between the 2 
subgroups (Table 3). In addition, abnormal findings in brain MRI 
were more common in the congenital­onset subgroup compared 
to that in the late­onset subgroup (85.7% vs. 50.0%, respectively), 
though not statistically significant. In the last out­patient follow­up 
visit, dependence on ventilator was higher in the congenital­onset 
subgroup compared to that in the late­onset subgroup (50.0% vs. 
0%, respectively), whereas the late­onset subgroup had fewer limits 
(in the mild form) on daily life.
Table 3. Diagnostic evaluation and functional status of patients with 





Elevated 4 (40.0) 1/6 (16.7) 0.346
Brain MRI findings (n=11)
Normal 1/7 (14.3) 2/4 (50.0) 0.279
Abnormal 6/7 (85.7) 2/4 (50.0) -
Signal changes of white matter 4/7 (57.1) 1/4 (25.0) 0.348
Atrophy of brain parenchyme 2/7 (28.6) 1/4 (25.0) 0.721
Need for respiratory support (n=17)
Independent 5 (50.0) 7 (100) 0.044
Dependent on ventilator 5 (50.0) 0 (0) 0.044
Activities of daily life (n=17)*
Mild 4 (40.0) 7 (100) 0.035
Moderate 2 (20.0) 0 (0) 0.331
Severe 4 (40.0) 0 (0) 0.103
Values are presented as number (%).
CK, creatinine kinase; MRI, magnetic resonance imaging.
*Mild: ambulatory and/or independent, moderate: WC and/or partially de-
pendent, severe: bed-ridden and/or totally dependent.
Table 4. General characteristics and clinical manifestations of patients 





Male 6 (66.7) 6 (75.0) 0.563
Female 3 (33.3) 2 (25.0) 0.563
First symptom
Hypotonia 6 (66.7) 4 (50.0) 0.419
Myotonia 0 (0) 2 (25.0) 0.206
Weakness 0 (0) 1 (12.5) 0.471
Delayed development 2 (22.2) 0 (0) 0.265
Gait disturbance 1 (11.1) 0 (0) 0.529
Chest discomfort 0 (0) 1 (12.5) 0.471
Birth history
Prenatal
Decreased fetal movements 1/6 (16.7) 1/6 (16.7) 0.773
Polyhydramnios 0/6 (0) 2/6 (33.3) 0.227
At birth
Prematurity
Preterm 5 (55.6) 1 (12.5) 0.088
Term 4 (44.4) 7 (87.5) 0.088
IUP
Less than 34 wk (<34 wk) 1 (11.1) 1 (12.5) 0.735
Between 34 wk and 37 wk 4 (44.4) 1 (12.5) 0.183
More than 37 wk (≥37 wk) 4 (44.4) 6 (75.0) 0.218
Birth weight
ELBW (<1,000 g) 0/8 (0) 0/7 (0) -
VLBW (<1,500 g) 0/8 (0) 0/7 (0) -
LBW (<2,500 g) 4/8 (50.0) 1/7 (14.3) 0.182
Normal (≥2,500 g) 4/8 (50.0) 6/7 (85.7) 0.182
IUGR 2/8 (25.0) 0/7 (0) 0.267
Perinatal asphyxia 4/8 (50.0) 3/5 (60.0) 0.587
NICU admission 6/8 (75.0) 4/5 (80.0) 0.685
Need for respiratory support 6/8 (75.0) 3/5 (60.0) 0.510
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3. Genetic subgrouping
1) General characteristics and clinical manifestations
As shown in Table 4, there were 6 male (66.7%) and 3 female 
patients (33.3%) in the large CTG subgroup and 6 males (75.0%) and 
1 fe male (25.0%) in the small CTG subgroup. This gender difference 
was, however, not statistically significant. In contrast to our findings 
from clinical subgrouping, we found no significant difference 
between the genetic subgroups for hypotonia as a first symptom, 
prematurity, NICU admission rate, need for respiratory support, 
and several other clinical symptoms. We found hypotonia as a first 
symptom in 66.7% of patients from the large CTG subgroup and in 
50.0% of patients from the small CTG subgroup, whereas the pro­
portion of premature birth was 55.6% in the large CTG subgroup 
versus 12.5% in the small CTG subgroup. The proportion of cases 
requiring NICU admis sion and need for respiratory support was both 
75.0% in the large CTG subgroup compared to 80.0% and 60.0%, 
respectively, in the small CTG subgroup. Poor feeding in neonate 
was found to be the only symptom that was significantly increased 
in patients in the large CTG subgroup, compared to that found in the 
small CTG sub group (88.9% vs. 25.0% respectively, P=0.015).
2) Diagnostic evaluation and functional status in the last visit
Similar to our findings from clinical subgroups, we found no sig­
ni ficant difference in CK level and abnormal findings from brain 
MRI between the 2 genetically defined subgroups (Table 5). In creased 
CK levels of 37.5% and 25.0% were found in the large CTG and small 
CTG subgroups respectively; we also found that 80.0% and 66.7% of 
patients from these 2 subgroups had abnormal findings in brain MRI. 
Similarly, we found no significant difference between the genetic 
subgroups based on ventilator dependence (33.3 % vs. 25.0%, 
respectively) and quality of daily life (55.6% vs. 75.0%, res pectively).
Discussion
Patients with DM1 do not always present typical symptoms of the 
Table 4. General characteristics and clinical manifestations of patients 






History of muscular disease 6 (66.7) 4 (50.0) 0.419
Period between birth, symptom 
onset, and genetic diagnosis (yr)
From birth to symptom onset 0.1 (0.1–9.9) 4.3 (0.1–14.9) 0.321
From symptom onset to diagnosis 0.1 (0.1–10.5) 0.85 (0.1–2.0) 0.606
From birth to diagnosis 0.1 (0.1–20.4) 5.35 (0.1–16.2) 0.139
Systemic involvements
Head and neck
Cataract 0 (0) 1 (12.5) 0.471
Cardiac
Arrhythmia 0 (0) 1 (12.5) 0.471
Gastrointestinal
Poor feeding in neonate 8 (88.9) 2 (25.0) 0.015
Dysphagia 6 (66.7) 3 (37.5) 0.238
Intestinal pseudo-obstruction 0 (0) 0 (0) -
Cholelithiasis 0 (0) 0 (0) -
Respiratory
Congenital respiratory distress 4 (44.4) 2 (25.0) 0.373
Muscular
Hypotonia in neonate 7 (77.8) 4 (50.0) 0.247
Myotonia 3/3 (100) 6/6 (100) -
Weakness 4/5 (80.0) 7/7 (100) 0.417
Myotonic discharges on EMG 1/1 (100) 2/5 (40.0) 0.088
Neurologic
Delayed development or MR 5/5 (100) 5 (62.5) 0.196
Age of onset
Neonate (<1 mo) 6 (66.7) 4 (50.0) 0.419
Infant and older (≥1 mo) 3 (33.3) 4 (50.0) 0.419
<5 yr 1 (11.1) 0 (0) 0.529
5–10 yr 2 (22.2 1 (12.5) 0.547
10–15 yr 0 (0) 3 (37.5) 0.082
Values are presented as number (%) or mean (range).
IUP, intrauterine pregnancy; ELBW, extremely low birth weight; VLBW, very low 
birth weight; LBW, low birth weight; IUGR, intrauterine growth restriction; NICU, 
neonatal intensive care unit; EMG, electromyogram; MR, mental retardation.
Table 5. Diagnostic evaluation and functional status of patients with 
myotonic dystrophy on the last visit based on genetic subgrouping (n=17)




Elevated 3/8 (37.5) 2/8 (25.0) 0.500
Brain MRI findings (n=11)
Normal 1/5 (20.0) 2/6 (33.3) 0.576
Abnormal 4/5 (80.0) 4/6 (66.7)
Signal changes of white matter 2/5 (40.0) 3/6 (50.0) 0.608
Atrophy of brain parenchyme 2/5 (40.0) 1/6 (16.7) 0.424
Need for respiratory support (n=17)
Independent 6 (66.7) 6 (75.0) 0.563
Dependent on ventilator 3 (33.3) 2 (25.0) 0.563
Limitations in daily life (n=17)*
Mild 5 (55.6) 6 (75.0) 0.373
Moderate 1 (11.1) 1 (12.5) 0.735
Severe 3 (33.3) 1 (12.5) 0.335
Values are presented as number (%).
CTG, cytosine/thymine/guanine; CK, creatinine kinase; MRI, magnetic reso­
nance imaging.
*Mild, ambulatory and/or independent; moderate, WC and/or partially depen-
dent; severe, bed-ridden and/or totally dependent.
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disease, but may show variable symptoms and severities. Variable 
instability of a CTG trinucleotide repeat in DMPK causes genotypic 
and phenotypic variation.10) Some studies have included patients 
with motor impairments and most patients may have several clinical 
features like myotonia, muscular weakness, and family history.10,11) 
We found variable symptoms in our study cohort as well. However, 
there have been few studies that subgrouped patients according to 
age of onset to compare prominent clinical features between groups. 
One study divided patients into 5 clinical categories (congenital, 
infantile, juvenile, adult­onset, and late­onset) and found that mus­
cle weakness typically arises earlier in the congenital group, whereas 
myotonia was the earliest prominent symptom in patients from the 
infantile group. Early cardiac defects were prominent in ju venile 
group, whereas secondary symptoms, such as cataract and endo­
crine disorders, were prominent in the adult­onset group.12) Based on 
clinical characteristics, we divided our study cohort into 2 groups, 
congenital­onset and late­onset, and found that there were several 
variables with statistically significant differences between these 2 
cohorts.
In our study, prematurity, NICU admission rate, need for respi­
ratory support, and hypotonia were important in the early period, 
while dysphagia, ventilator dependence, and functional status 
became important in the long­term. A previous study with 169 
patients with DM1 had shown that over half the number reported 
swallowing problems, whose major contributor seemed to be mus­
cular weakness. Further, researchers found that swallowing ab nor­
malities may be present even if only a few symptoms were reported, 
or severity of the disease was not much pronounced.13) Therefore, 
serial check­ups for swallowing may be warranted in clinical follow­
up visits for patients with DM1. Furthermore, al though pulmonary 
function impairment is relatively slow in patients with DM1, com­
pared to that in patients with other neuromu scular disorders, we 
need to carefully assess respiratory symptoms and rou tinely perform 
screening tests since respiratory impair ment is a major cause of 
death among patients with DM1.14) Therefore, al though all the symp­
toms of DM1 are important for such a variable disease, longitudinal 
monitoring of certain clinical variables is required for affect ed indi­
viduals.
Individuals with DM1 inherently present a variable genotype 
that is dependent on the number of CTG repeats in DMPK. In our 
study, we found that patients exhibited a wide range of CTG­repeat 
length, ranging from 100 to more than 2,000 repeats. However, on 
the basis of genetic subgrouping, and in contrast to our finding from 
clinical subgrouping, we found poor feeding in neonate as the only 
variable that was statistically significant when compared between 
the 2 genetically defined subgroups. In contrast, a previous study 
had shown that patients with DM1 along with muscular weakness 
or dysfunction of the central nervous system also harbored larger 
CTG expansions compared to those without either symptom.10) 
Fur thermore, many studies have reported that age of onset was in­
versely correlated with the CTG repeat length10,11); however, others 
argued that the correlation between age of onset and CTG repeat 
length was only significant for patients with small expansions.15,16) 
In our current study, we found no evidence of association between 
the length of CTG repeats and age of onset, although all of the 
patients from our cohort were less than 15 years of age. Collectively, 
these findings demonstrate the challenges involved in genotype­
phenotype correlations. If age of onset and CTG repeat­length were 
inversely correlated, we would expect our findings, based on genetic 
subgrouping, to be similar to that of clinical subgrouping, which 
had shown evidence of association. Admittedly, in addition to the 
scarcity of the disease, our findings may not be generalizable due to 
the small number of patients evaluated, as well as, the fact that they 
were all under 15 years of age. Nevertheless, we cannot rule out the 
possibility of having no correlation between these factors at all, or of 
such associations being population­specific. In addition, since this 
is a retrospective study, there may be biases or errors in the medical 
records that may affect our study outcomes. Thus, further studies are 
warranted with a larger group of well­characterized patients.
Undoubtedly, a genetic approach is important for diagnosis since 
clinical symptoms of DM are not always specific; however, in reality, 
most diagnostic approach of DM1 is based on clinical symptoms as 
well, since it is necessary to make diagnostic estimates using several 
clues, unless a family history has been determined or confirmatory 
genetic testing is performed. In other words, clinical suspicion is 
the first step in diagnosis before confirmatory examinations, such 
as genetic tests, are performed. De Antonio et al.12) had stated that 
age of onset and clinical form may be the key criteria in the design 
of clinical trials, when considering DM1 health management and 
research. Similarly, it is important to detect clinical clues from pati­
ents, including age of onset, and to know what characteristics to 
look for. Such efforts help in prognosis and preparation of proper 
management approach tailored for each patient; these could not be 
achieved simply from the number of CTG repeats.
Since DM1 has variable phenotypes and genotypes, there is no 
typical natural course or established management guidelines for 
patients with DM1. Serial examinations to detect newly developed 
abnormal signs and symptoms, for early treatment, need to be 
performed. Although some studies have recommended a series of 
examinations, they are general screening tools that are not based 
on individual parameters from patients.17,18) For example, annual slit 
lamp examination of the lens (cataracts), pulmonary function test 
(respiratory failture), polysomnography (central/obstructive apnea), 
electrocardiogram (conduction disorder) and periodic thyroid 
function test (thyroid dysfunction), echocardiogram or cardiac 
magnetic resonance imaging (cardiomyopathy) are recommended. 
Therefore, several studies, such as PhenoDM1,19) are underway to 
unravel the natural course of DM1 and achieve better outcomes. It 
is through these studies that a concrete and distinct protocol for the 
management of DM1 may be established, and many clinical features 
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will play an important role in this process.
To summarize, we demonstrate the advantage of evaluating clini­
cal variables through subgrouping in our small cohort of patients 
with DM1. Since DM is a rare disease, large prospective studies are 
difficult to perform; however, more large­scale studies are needed to 
develop individualized management protocols, based on the natural 
course of the disease and each patient’s clinical characteristics; 
proper subgroup analyses, as in this study, will contribute to achieve 
this important goal for patients with DM1.
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